1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: EORTC-1207, 2012-002317-18, NCT01646554
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AFLIBC06097, 2011-005724-17, U1111-1125-8949, NCT01571284
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AFLIBL06266, 2012-000048-89, U1111-1128-9325, NCT01670721
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC11338, U1111-1115-7227, NCT01661270
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00037688, NCT01661972
|
|
6.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00559, U10CA021115, CDR0000489069, E4805, ECOG-E4805, NCT00357760
|
|
7.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYWCCC-0608008688, 0608008688, 7521, NCT00437034
|
|
8.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 16
Sponsor: NCI
Protocol IDs: CHNMC-PHII-107, PHII-107, 8628, NCT01258855
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSU 11182, NCI-2012-01167, NCT01652196
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: BrUOG C261, NCT01669720
|
|
11.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: R910-ST-1114, NCT01688960
|
Mobile | Español
